Trial reportJournal of pain research2025
Median Effective Volume of 0.25% Ropivacaine for Bilateral Transversus Thoracis Muscle Plane Block in Patients Undergoing Open Cardiac Surgery.
Trial report in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The median effective dose of ropivacaine required to achieve an effective transversus thoracis muscle plane block (TTP) has not been established. This study aimed to determine the EV50 of 0.25% ropivacaine for TTP using Dixon's up-and-down method. Methods: This prospective study involved 21 patients with American Society of Anesthesiologists physical status II to III, aged 20 to 60 years, with a BMI of 18 to 30 kg/m², who were scheduled for open cardiac surgery. Bilateral TTP was performed preoperatively, and 30 minutes post-block, the cold sensory decrease area (CSDA) was marked and recorded. The initial volume of 0.25% ropivacaine administered was 20mL. The effective block was defined as the CSDA encompassing thoracic nerves 2 to 6, which dictated a 2 mL increment or decrement in the subsequent patient's dosage. The study concluded when volumes reached 5 mL or 40 mL for 7 patients, or after 7 turning points. Results: A total of 21 cases were evaluated. Twelve (57.1%) of 40 received an effective block, while nine (42.9%) patients received a non-effective block. Analysis using SPSS 26.0 revealed the median effective volume (EV50) of 16.36mL for 0.25% ropivacaine and the 95% effective volume (EV95) of 19.81mL. Conclusion: In open cardiac surgery, the median effective volume of 0.25% ropivacaine for TTP is 16.36 mL (95% CI 14.35 to 18.43), while the 95% effective volume is 19.81 mL (95% CI 18.60 to 22.75). Trial Registration Number: ChiCTR2300073449.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.